Hope for myelofibrosis patients: new drug combo aims to shrink spleens and ease symptoms
Disease control
Recruiting now
This study tests whether adding navtemadlin to the standard drug ruxolitinib helps people with myelofibrosis who aren't getting enough benefit from ruxolitinib alone. About 600 adults with myelofibrosis will first take ruxolitinib, then those with a poor response will be randomly…
Phase: PHASE3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC